Literature DB >> 30048589

3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.

Younis Baqi1, Thanigaimalai Pillaiyar2, Aliaa Abdelrahman2, Olesja Kaufmann2, Samer Alshaibani2, Muhammad Rafehi2, Saman Ghasimi2, Rhalid Akkari2, Kirsten Ritter2, Katharina Simon3, Andreas Spinrath3, Evi Kostenis3, Qiang Zhao4, Meryem Köse2, Vigneshwaran Namasivayam2, Christa E Müller2.   

Abstract

The orphan receptor GPR17 may be a novel drug target for inflammatory diseases. 3-(2-Carboxyethyl)-4,6-dichloro-1 H-indole-2-carboxylic acid (MDL29,951, 1) was previously identified as a moderately potent GPR17 agonist. In the present study, we investigated the structure-activity relationships (SARs) of 1. Substitution of the indole 1-, 5-, or 7-position was detrimental. Only small substituents were tolerated in the 4-position while the 6-position accommodated large lipophilic residues. Among the most potent compounds were 3-(2-carboxyethyl)-1 H-indole-2-carboxylic acid derivatives containing the following substituents: 6-phenoxy (26, PSB-1737, EC50 270 nM), 4-fluoro-6-bromo (33, PSB-18422, EC50 27.9 nM), 4-fluoro-6-iodo (35, PSB-18484, EC50 32.1 nM), and 4-chloro-6-hexyloxy (43, PSB-1767, EC50 67.0 nM). (3-(2-Carboxyethyl)-6-hexyloxy-1 H-indole-2-carboxylic acid (39, PSB-17183, EC50 115 nM) behaved as a partial agonist. Selected potent compounds tested at human P2Y receptor subtypes showed high selectivity for GPR17. Docking into a homology model of the human GPR17 and molecular dynamic simulation studies rationalized the observed SARs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30048589     DOI: 10.1021/acs.jmedchem.7b01768

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.

Authors:  Chiara Parravicini; Davide Lecca; Davide Marangon; Giusy Tindara Coppolino; Simona Daniele; Elisabetta Bonfanti; Marta Fumagalli; Luca Raveglia; Claudia Martini; Elisabetta Gianazza; Maria Letizia Trincavelli; Maria P Abbracchio; Ivano Eberini
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

2.  Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.

Authors:  Julian Breidenbach; Carina Lemke; Thanigaimalai Pillaiyar; Laura Schäkel; Ghazl Al Hamwi; Miriam Diett; Robin Gedschold; Nina Geiger; Vittoria Lopez; Salahuddin Mirza; Vigneshwaran Namasivayam; Anke C Schiedel; Katharina Sylvester; Dominik Thimm; Christin Vielmuth; Lan Phuong Vu; Maria Zyulina; Jochen Bodem; Michael Gütschow; Christa E Müller
Journal:  Angew Chem Int Ed Engl       Date:  2021-03-24       Impact factor: 16.823

3.  Involvement of GPR17 in Neuronal Fibre Outgrowth.

Authors:  Max Braune; Nico Scherf; Claudia Heine; Katja Sygnecka; Thanigaimalai Pillaiyar; Chiara Parravicini; Bernd Heimrich; Maria P Abbracchio; Christa E Müller; Heike Franke
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.